Nxera Pharma (4565) Q1 2025 earnings summary

Executive summary

• Revenue surged 126% year-over-year to JPY 28.8 billion, driven by full-year Pivlaz sales, milestone payments from partnered programs, and M&A activity.

• Core operating profit reached JPY 3.6 billion, reversing a prior year loss, while accounting operating profit was impacted by JPY 9 billion in non-core expenses, mainly from M&A-related costs that will not recur in 2025.

• Cash balance declined to JPY 36.2 billion due to advanced API purchases for QUVIVIQ's launch and integration activities.

• Major pipeline progress included new deals, successful clinical milestones, and expansion of commercialized products in Japan and APAC.

• Multiple clinical and commercial partnerships advanced, including with Boehringer Ingelheim, Shionogi, Neurocrine, Centessa, and Pfizer.

Financial highlights

• Revenue increased to JPY 28.8 billion from JPY 12.8 billion year-over-year, mainly from Pivlaz and milestone payments.

• Milestone revenue jumped from JPY 2.3 billion to JPY 11.2 billion, with significant payments from Neurocrine and AbbVie.

• Core operating profit improved by JPY 3.6 billion; accounting operating profit was a loss of JPY 5.4 billion due to non-core expenses.

• Non-core expenses of JPY 9 billion, mainly M&A-related, will not recur in 2025.

• Cash decreased to JPY 36.2 billion, primarily due to inventory build-up for QUVIVIQ.

Outlook and guidance

• 2025 revenue targets: Pivlaz JPY 13–14 billion, QUVIVIQ JPY 4–5 billion, combined JPY 17–19 billion.

• R&D expenses forecasted at JPY 12–14 billion, up from JPY 11.8 billion, reflecting clinical progress.

• SG&A expenses expected to remain flat or slightly decrease as integration efficiencies offset increased amortization and IT investments.

• IFRS operating profit in 2025 depends on Boehringer Ingelheim exercising its GPR52 license; otherwise, profit is closer to break-even.

• No consolidated full-year forecast due to variability in milestone and upfront payments.